Ladiratuzumab vedotin (SGN-LIV1A) 是一种 LIV-1 靶向的抗体药物偶联物 (ADC) (IC50: 5.6 nM)。Ladiratuzumab vedotin 由人源化 IgG1 单克隆抗体、MMAE 和蛋白酶-可切割型连接子组成。Ladiratuzumab vedotin 可以驱动免疫原性细胞死亡 (ICD) 以引发免疫反应。Ladiratuzumab vedotin 可用于乳腺癌研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

Anti-LIV-1 / SLC39A6 Reference Antibody ((ladiratuzumab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-LIV-1 / SLC39A6 Reference Antibody ((ladiratuzumab vedotin) is 98.2%, determined by SEC-HPLC.

Immobilized human LIV 1, His Tag at 2 ug/mL can bind Anti-LIV-1 / SLC39A6 Reference Antibody ((ladiratuzumab vedotin), EC50=0.007652 ug/mL.

Human LIV1 CHOS cells were stained with Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab vedotin) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.07456 ug/mL.

The killing ratio ladiratuzumab vedotin by Human LIV-1 HEK293 Cell Line increased with the increase of antibody concentration, and the killing Rate (%) reached 74%

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.